Searchable abstracts of presentations at key conferences in endocrinology

ea0025p23 | Bone | SFEBES2011

Ablation of AMP-activated protein kinase (AMPK) α1 catalytic subunit in mice leads to decreased bone loss after ovariectomy and impaired bone response to intermittent PTH treatment

Shah Mittal , Viollet Benoit , Korbonits Marta , Chenu Chantal

AMPK is a key regulator of cellular and body energy homeostasis. We previously demonstrated that AMPK activation in osteoblasts increases bone formation in vitro while deletion of the AMPKα1 subunit leads to decreased bone mass in vivo. To determine whether bone turnover can be stimulated in the absence of AMPKα1 subunit, we subjected WT and AMPKα1−/− mice to catabolic (ovariectomy: OVX) and anabolic (intermittent PTH adminis...

ea0038p6 | Bone | SFEBES2015

Increased circulating sclerostin levels in type 2 diabetic rats are not associated with changes in bone sclerostin production

Pereira Marie , Gohin Stephanie , Lund Nina , Hvid Anne , Smitham Peter , Oddy Michael , Reichert Ines , Chenu Chantal

Type 2 Diabetes Mellitus (T2DM) is associated with decreased bone quality and a higher prevalence of fractures. Sclerostin is an inhibitor of bone formation produced by osteocytes and its expression is elevated in serum of diabetic patients. We examined the effect of T2DM on bone architecture and sclerostin levels in a rat model of T2DM and the influence of hyperglycaemia on sclerostin production by bone cells in vitro. Bone architecture was measured by microCT in 14 ...

ea0034p8 | Bone | SFEBES2014

Liraglutide, a glucagon-like peptide-1 receptor agonist, improves bone mass and architecture in ovariectomised mice

Pereira Marie , Jeyabalan Jeshmi , Jorgensen Camilla Sofie , Cleasby Mark , Hopkinson Mark , Chenu Chantal

The increased incidence of type 2 diabetes mellitus (T2DM) among the aged is associated with an impaired skeletal structure and a higher prevalence for bone fractures. Besides, anti-diabetic therapies can also negatively affect bone mass. In this study, we tested the skeletal effects of chronic administration of two glucagon-like peptide receptor (GLP-1R) agonists and examined the expression of GLP-1R in bone tissue and cells. Twelve week-old female C57Bl/6N mice were ovariect...

ea0031p8 | Bone | SFEBES2013

Excessive GH expression in bGH transgenic mice adversely alters bone architecture and quality

Lim Su-Vern , Marenzana Massimo , List Edward , Kopchick John , Korbonits Marta , Chenu Chantal

GH is an important anabolic hormone involved in the regulation of longitudinal bone growth. However, acromegaly patients have a higher prevalence of vertebral fractures despite normal bone mineral density (BMD), suggesting that overexpression of GH has adverse effects on skeletal architecture and strength. We used giant bovine GH (bGH) transgenic mice to analyse the effects of high serum GH levels on bone architecture and mechanical strength. Five month-old hemizygous male bGH...

ea0021p22 | Bone | SFEBES2009

AMP-activated protein kinase (AMPK) regulates in vitro bone formation and bone mass in vivo

Shah Mittal , Bataveljic Attia , Violet Benoit , Arnett Tim , Saxon Leanne , Korbonits Marta , Chenu Chantal

Adenosine 5′-monophosphate-activated protein kinase (AMPK), a regulator of energy homeostasis, has a central role in mediating the appetite-modulating and metabolic effects of many hormones and neuromodulators. We previously demonstrated similar neuroendocrine activation of AMPK in bone-forming osteoblasts. In this study, we tested whether stimulation of AMPK activity in osteoblasts plays a role in their function and whether deletion of the catalytic AMPKα1 subunit,...